Ultime notizie per Asahi Intecc (OTC:AHICF) Azioni

Asahi Intecc Co Ltd develops, manufactures, and sells medical devices. The firm operates in two segments: medical and device. The medical segment generates the vast majority of revenue and sells a range of guide wires and catheters for treatment and examination. The device segment sells components to medical and industrial companies, such as hollow cable tubes, catheter delivery systems, and stainless steel rope. Asahi's products are used in a variety of industries, including the medical, construction, automobile, office automation equipment, and electric appliance industries. Asahi generates the largest proportion of its revenue in Japan.

ASAHI INTEC CO LTD by Asahi Intec Co., Ltd.

Asahi Intecc Co Ltd

Throughout the last three months, 10 analysts have evaluated StepStone Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STEP#NASDAQ">STEP</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $60.4, a high estimate of $73.00, and a low estimate of $52.00. Witnessing a positive shift, the current average has risen by 16.04% from the previous average price target of $52.05.
<img src="https://www.benzinga.com/files/images/story/2024/1731607231_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The analysis of recent analyst actions sheds light on the perception of StepStone Group by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$65.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Adam Beatty</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$65.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Chris Kotowski</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$73.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>John Dunn</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$55.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$60.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$61.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Kenneth Worthington</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$61.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Alexander Blostein</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$57.00</td>
<td>$51.50</td>
</tr>
<tr>
<td>Adam Beatty</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$55.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$52.00</td>
<td>$43.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to StepStone Group. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of StepStone Group compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for StepStone Group's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into StepStone Group's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/STEP/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on StepStone Group analyst ratings.</a>
<h2>Unveiling the Story Behind StepStone Group</h2>
StepStone Group Inc operates as a fully integrated private markets solution provider. The company provides customized investment solutions and advisory and data services. It provides investment solutions in the areas of private equity, real estate, private debt, and infrastructure and real assets. The company consists of a single operating segment and a single reportable segment for accounting and financial reporting purposes.
<h3>Understanding the Numbers: StepStone Group's Finances</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: StepStone Group's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 41.93%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Financials sector.
Net Margin: StepStone Group's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 6.49%, the company may face hurdles in effective cost management.
Return on Equity (ROE): StepStone Group's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 4.61%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.45%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.73, StepStone Group adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

STEP

Breaking Down StepStone Group: 10 Analysts Share Their Views

Ratings for Archrock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AROC#NYSE">AROC</a>) were provided by 6 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $24.83, a high estimate of $27.00, and a low estimate of $24.00. This current average has increased by 3.46% from the previous average price target of $24.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1731607223_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The perception of Archrock by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elvira Scotto</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$27.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Elvira Scotto</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$26.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Gabriel Moreen</td>
<td>Mizuho</td>
<td>Announces</td>
<td>Outperform</td>
<td>$24.00</td>
<td>-</td>
</tr>
<tr>
<td>Douglas Irwin</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Buy</td>
<td>$24.00</td>
<td>-</td>
</tr>
<tr>
<td>Durgesh Chopra</td>
<td>Evercore ISI Group</td>
<td>Announces</td>
<td>Outperform</td>
<td>$24.00</td>
<td>-</td>
</tr>
<tr>
<td>Jeremy Tonet</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Overweight</td>
<td>$24.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Archrock. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Archrock compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Archrock's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into Archrock's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/AROC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Archrock analyst ratings.</a>
<h2>Unveiling the Story Behind Archrock</h2>
Archrock Inc is an energy infrastructure company with focus on midstream natural gas compression and a commitment to helping customers produce, compress and transport natural gas. It has two business segments, Contract Operations, and Aftermarket Services. Under the umbrella of contract operations services, the company provides operations to meet customers' natural gas compression needs. Services include designing, owning, installing, operating, and maintaining equipment. Aftermarket Services business provides a full range of services to support the compression needs of customers that own compression equipment, including operations, maintenance, overhaul and reconfiguration services and sales of parts and components. It generates maximum revenue from the Contract Operations segment.
<h3>Archrock's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Archrock's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 9.28%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Energy sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Archrock's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 12.56% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Archrock's ROE excels beyond industry benchmarks, reaching 3.83%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Archrock's ROA excels beyond industry benchmarks, reaching 1.27%. This signifies efficient management of assets and strong financial health.
Debt Management: Archrock's debt-to-equity ratio is below the industry average. With a ratio of 1.81, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AROC

The Analyst Landscape: 6 Takes On Archrock

The U.S. Food and Drug Administration (FDA) has offered positive feedback to CaaMTech, Inc. on its CT-4201 psilocin prodrug program, specifically endorsing the company's approach to addressing "functional unblinding" in <a href="https://www.benzinga.com/markets/psychedelics">its drug trials. </a>
This regulatory milestone not only clears the clinical pathway for CT-4201's development but also signals significant progress in psychedelic-assisted therapy for mental health, particularly for Major Depressive Disorder (MDD).
<h3 class="wp-block-heading">Clearing Regulatory Hurdles for Psychedelic Therapy</h3>
Since 2016, CaaMTech has emerged as a frontrunner in serotonin science, focused on advancing novel serotonergic compounds. 
See Also: <a href="https://www.benzinga.com/general/health-care/24/11/41886800/u-s-election-stress-fuels-demand-for-psychedelic-assisted-therapy">U.S. Election Stress Fuels Demand For Psychedelic-Assisted Therapy</a>
CT-4201, a psilocin prodrug, represents the company's most promising development to date. Designed to improve upon the pharmacokinetic properties of psilocybin, a naturally occurring prodrug of psilocin found in "magic mushrooms," CT-4201 aims to enhance therapeutic effectiveness in MDD treatment.
Although psilocybin has been granted "Breakthrough Therapy" designation for its potential in treating depression, it remains a Schedule I substance and is not yet FDA-approved for medical use.
Psychedelic therapies, including psilocybin, have shown potential to deliver lasting relief from depression, even after a single dose. However, the effectiveness of these trials often faces a critical challenge: functional unblinding. 
This phenomenon occurs when participants can distinguish between receiving an active drug or placebo, particularly with drugs that produce noticeable psychoactive effects, such as psychedelics. Addressing functional unblinding is a critical requirement for regulatory agencies, as demonstrated by recent FDA actions.
<h3 class="wp-block-heading">Functional Unblinding: A Major Roadblock</h3>
In recent months, several psychedelic drug developers have encountered regulatory setbacks. For instance, Lykos Therapeutics Inc's application for MDMA-assisted therapy for PTSD was rejected due to concerns over functional unblinding. Similarly, COMPASS Pathways PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPS#NASDAQ">CMPS</a>) faced delays in its phase 3 psilocybin trials for treatment-resistant depression (TRD) amid "increased regulatory scrutiny" on the unblinding issue.
Drawing on insights from these previous regulatory interactions, CaaMTech refined its approach to unblinding, incorporating key lessons from the psychedelic research community. 
"Functional unblinding was a major barrier to the approval of psychedelics as medicines to treat the patients who need them most,&#8221; Dr. Andrew Chadeayne, CEO of CaaMTech stated.
"I'm incredibly proud that CaaMTech was able to solve this problem impeding the leading edge of psychedelic drug development," he added.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/24/11/41916504/patents-reveal-new-prodrugs-for-psilocin-promising-reliable-mental-health-treatments">Patents Reveal New Prodrugs For Psilocin, Promising Reliable Mental Health Treatments</a></li>
</ul>
Cover image made with AI.

Cannabis

News

Psychedelics

Health Care

Markets

CMPS

FDA Endorses CaaMTech's Psilocin Drug Development For Depression Treatment

WIIM

Equillium shares are trading lower after the company reported worse-than-expected Q3 sales results.

Analysts' ratings for Workday (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>) over the last quarter vary from bullish to bearish, as provided by 22 analysts.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">10</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">4</td>
<td align="right">7</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Workday and provided 12-month price targets. The average target is $294.05, accompanied by a high estimate of $350.00 and a low estimate of $255.00. This upward trend is evident, with the current average reflecting a 3.14% increase from the previous average price target of $285.09.
<img src="https://www.benzinga.com/files/images/story/2024/1731607212_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A comprehensive examination of how financial experts perceive Workday is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yun Kim</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Hold</td>
<td>$270.00</td>
<td>$255.00</td>
</tr>
<tr>
<td>Steven Enders</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$270.00</td>
<td>$274.00</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$315.00</td>
<td>$315.00</td>
</tr>
<tr>
<td>Kash Rangan</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$305.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Daniel Jester</td>
<td>BMO Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$300.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$285.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>David Hynes</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$300.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$289.00</td>
<td>$286.00</td>
</tr>
<tr>
<td>Jason Celino</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$305.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Kirk Materne</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$310.00</td>
<td>$290.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Neutral</td>
<td>$270.00</td>
<td>$255.00</td>
</tr>
<tr>
<td>David Hynes</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$300.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Yun Kim</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Hold</td>
<td>$255.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$350.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Brad Reback</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$270.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Keith Weiss</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$315.00</td>
<td>$325.00</td>
</tr>
<tr>
<td>Brad Zelnick</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$275.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Brad Sills</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$310.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$285.00</td>
<td>$262.00</td>
</tr>
<tr>
<td>Kirk Materne</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$290.00</td>
<td>$300.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Workday. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Workday compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Workday's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/WDAY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Workday analyst ratings.</a>
<h2>Discovering Workday: A Closer Look</h2>
Workday is a software company that offers human capital management, or HCM, financial management, and business planning solutions. Known for being a cloud-only software provider, Workday is headquartered in Pleasanton, California. Founded in 2005, Workday now employs over 18,000 employees.
<h3>Workday's Financial Performance</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Positive Revenue Trend: Examining Workday's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 16.68% as of 31 July, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: Workday's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 6.33%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Workday's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 1.6%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Workday's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.82%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Workday's debt-to-equity ratio is below the industry average at 0.4, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>What Are Analyst Ratings?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

WDAY

Expert Outlook: Workday Through The Eyes Of 22 Analysts

ZOOZ

ZOOZ Power shares are trading lower after the company announced it entered into an equity purchase agreement.

IMMP

Immutep shares are trading higher after the company announced the presentation of new data from EFTISARC-NEO, a Phase II investigator-initiated trial of eftilagimod alpha in combination with radiotherapy plus KEYTRUDA for patients with soft tissue sarcoma, at the CTOS 2024 Annual Meeting.

Barclays analyst Brandon Oglenski maintains Delta Air Lines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>) with a Overweight and raises the price target from $60 to $90.

Price Target

Barclays Maintains Overweight on Delta Air Lines, Raises Price Target to $90

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates Ocugen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCGN#NASDAQ">OCGN</a>) with a Buy and maintains $7 price target.

Reiteration

OCGN

HC Wainwright & Co. Reiterates Buy on Ocugen, Maintains $7 Price Target

Loop Capital analyst Yun Kim maintains Workday (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>) with a Hold and raises the price target from $255 to $270.

Loop Capital Maintains Hold on Workday, Raises Price Target to $270

Barclays analyst Brandon Oglenski maintains Allegiant Travel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGT#NASDAQ">ALGT</a>) with a Equal-Weight and raises the price target from $50 to $75.

ALGT

Barclays Maintains Equal-Weight on Allegiant Travel, Raises Price Target to $75

Palatin Technologies shares are trading lower. The company reported Q1 financial results.

MSFT

Microsoft shares are trading lower following a report suggesting U.S. regulators announced plans to investigate the company's cloud business practices.

Loop Capital analyst Yun Kim maintains Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) with a Hold and raises the price target from $270 to $340.

Loop Capital Maintains Hold on Salesforce, Raises Price Target to $340

Needham analyst Mayank Tandon maintains Endava (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAVA#NYSE">DAVA</a>) with a Buy and raises the price target from $33 to $36.

DAVA

Needham Maintains Buy on Endava, Raises Price Target to $36

BFRI

Biofrontera shares are trading lower after the company reported worse-than-expected Q3 financial results.

Loop Capital analyst Alton Stump maintains Cava Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAVA#NYSE">CAVA</a>) with a Hold and raises the price target from $122 to $147.

CAVA

Loop Capital Maintains Hold on Cava Group, Raises Price Target to $147

Beyond Meat, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BYND#NASDAQ">BYND</a>) shares are up on Thursday following the announcement of its latest product innovation, Beyond Sun Sausage, which is now rolling out <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41973205/beyond-sun-sausage-expands-to-whole-foods-market" rel="noreferrer noopener">nationwide at Whole Foods Market stores</a>.
This new plant-based sausage expands Beyond Meat&#8217;s product portfolio by offering an alternative that doesn&#8217;t aim to replicate traditional meat products but instead stands as its own protein option.
Unlike Beyond Meat&#8217;s typical offerings, Beyond Sun Sausage has plant-based ingredients such as spinach, bell peppers, yellow pea, brown rice, and red lentils. The product is available in two flavors—Beyond Sun Sausage Pesto, that is now available at all Whole Foods stores, and Beyond Sun Sausage Cajun, available at select locations.
Beyond Sun Sausage offers 12g of protein per link from a blend of plant-based proteins and is made with heart-healthy avocado oil, containing just 1g of saturated fat and no cholesterol.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/24/11/41788941/beyond-meat-returns-to-growth-in-q3-revenue-beat-eps-beat-cash-reserves-in-focus" rel="noreferrer noopener">Beyond Meat Returns To Growth In Q3: Revenue Beat, EPS Beat, Cash Reserves In Focus</a>
The product has earned certifications from the American Heart Association&#8217;s Heart-Check program and the American Diabetes Association&#8217;s Better Choices for Life program.
This launch follows Beyond Meat&#8217;s recent health-focused reformulation of its core products, reinforcing the company&#8217;s commitment to providing nutritious, sustainable, and accessible plant-based options.
Earlier this month, the company revised its full-year 2024 revenue outlook from a range of $320 million to $340 million to a new range of <a target="_blank" href="https://www.benzinga.com//node/41788941" rel="noreferrer noopener">$320 million to $330 million.</a>
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, BYND stock has lost over 20% in the past year.
Price Action: BYND shares are trading higher by 1.7% to $5.35&nbsp;at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/41980065/wynn-resorts-stock-surges-as-tilman-fertitta-increases-stake" target="_blank" rel="noreferrer noopener">Wynn Resorts Stock Surges As Tilman Fertitta Increases Stake</a></li>
</ul>

Equities

Movers

General

BYND

What's Going On With Beyond Meat Stock Today?

Barclays analyst Brandon Oglenski maintains Alaska Air Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALK#NYSE">ALK</a>) with a Overweight and raises the price target from $55 to $80.

Barclays Maintains Overweight on Alaska Air Gr, Raises Price Target to $80

SGMT

Sagimet Biosciences shares are trading lower after the company reported worse-than-expected Q3 EPS results.

Asahi Intecc Co (JP:7747) has released an update. Asahi Intecc Co., Ltd has announced an increase in its year-end dividend to 20.37 yen per share, ...

Asahi Intecc Announces Increased Year-End Dividend

Asahi Intecc Co (JP:7747) has released an update. Asahi Intecc Co. reports a robust financial performance for the fiscal year ended June 30, 2024, ...

Asahi Intecc Co. Reports Strong Financial Growth

Asahi Intecc Co (JP:7747) has released an update. Asahi Intecc Co., Ltd. has announced a change in leadership, with Masahiko Miyata stepping down a...

Asahi Intecc Announces Executive Leadership Transition

Asahi Intecc Co (JP:7747) has released an update. Asahi Intecc Co reported an 8.6% year-on-year revenue increase for Q1 of fiscal year ending June ...

Asahi Intecc Sees Revenue Boost Amid Yen Depreciation

Asahi Intecc Co (JP:7747) has released an update. Asahi Intecc Co. is expanding its footprint in the Chinese market by establishing a new subsidiar...

Asahi Intecc Expands in China with New Subsidiary

Asahi Intecc Co (JP:7747) has released an update. Asahi Intecc Co. has released its 2024 Integrated Report, which provides insights into its value ...

Asahi Intecc Unveils 2024 Integrated Report

Asahi Intecc Co (JP:7747) has released an update. Asahi Intecc Co. has announced its acquisition of all shares in Nitta Mold Co., Ltd., intending t...

Comments

Asahi Intecc

Notizie

Ultime notizie per Asahi Intecc (OTC:AHICF) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO